Side-by-side comparison of AI visibility scores, market position, and capabilities
US mid-size airline with $9B revenue; premium Mint business class and free snacks/WiFi positioning post-DOJ blocking of Spirit acquisition and American Airlines alliance.
JetBlue Airways is a mid-size US airline known for its customer experience focus — offering free snacks, live television at every seat (Fly-Fi in-flight wifi), extra legroom (Even More Space seats), and a friendly cabin atmosphere at competitive prices. Listed on NASDAQ (NASDAQ: JBLU) and headquartered in Long Island City, New York, JetBlue generates approximately $9 billion in annual revenue and operates primarily in the northeastern US, Florida, Caribbean, and transcontinental routes. JetBlue has positioned itself as a "high-class, low-cost" carrier between the ultra-low-cost spirit and the network carriers.\n\nJetBlue's fleet consists primarily of Airbus A320 family aircraft and Airbus A220s, with the Airbus A321LR and A321XLR enabling its transatlantic expansion. JetBlue Mint — the airline's premium transcontinental and transatlantic business class product with lie-flat seats — has been a critically acclaimed success, competing favorably with Delta's first class and United Polaris on key routes. The TrueBlue loyalty program and the expanded Northeast Alliance with American Airlines (blocked by DOJ in 2023) have shaped JetBlue's competitive positioning.\n\nIn 2025, JetBlue faces significant financial and strategic challenges: the DOJ successfully blocked both the American Airlines alliance and the Spirit Airlines acquisition, leaving JetBlue without the scale benefits it had been counting on. The airline has significant debt and has been executing a cost-cutting plan ("JetForward") that involves reducing routes, retiring older aircraft, and cutting capacity to improve profitability. JetBlue competes with Delta, American, United, and Southwest for the leisure and business traveler. The 2025 strategy focuses on the JetForward financial recovery plan, growing JetBlue Mint transatlantic routes profitably, and stabilizing the core domestic network.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.